BioSpace News Archive

While much of the mystery surrounding sepsis remains, Feinstein Institutes for Medical Research scientists published in Cellular & Molecular Immunology the discovery of a protein that inhibits the body’s ability to clear bacteria, opening new avenues of therapeutic research.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, announced the closing of a €130 million Series C equity financing.

Mission Bio announced a new publication in Nature from researchers at the Ragon Institute of MGH, MIT, and Harvard and Brigham and Women’s Hospital using Mission Bio’s Tapestri® Platform to identify phenotypic signatures of hidden human immunodeficiency virus 1 -infected immune cells that allow the virus to evade immune response.

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, announced the appointment of two new directors to its Board of Directors.

Zensights LLC has named Barry Brandstetter to its advisory board, effective January 2, 2023.

HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for HFB200603.

RemSleep Holdings Inc., a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients, provides a corporate update and letter to shareholders from CEO Tom Wood.

Eisai Co., Ltd. and Biogen Inc. announced today that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb (Brand Name in the U.S.: LEQEMBI™).

LEQEMBI™ has the potential to make a difference for people living with early Alzheimer’s disease, their loved ones and healthcare professionals, and was recently approved by the U.S. Food and Drug Administration for the treatment of AD.

Based on hhc concept, our corporate philosophy, Eisai is committed to improve patients health outcomes and quality of life, simplify care delivery, increase health system efficiency and spur future investments in Alzheimer’s disease.